FAM13A Represses AMPK Activity and Regulates Hepatic Glucose and Lipid Metabolism

HIGHLIGHTS

SNP rs2276936 regulates expression of endogenous FAM13A

Fam13a−/− mice are protected from high-fat-diet-induced obesity and fatty liver.

Fam13a−/− hepatocytes show increased mitochondrial respiration and AMPK activity

Lin et al., iScience 23, 100928
March 27, 2020 © 2020 The Authors.
https://doi.org/10.1016/j.isci.2020.100928
Article

FAM13A Represses AMPK Activity and Regulates Hepatic Glucose and Lipid Metabolism

Xin Lin,1,4 Yae-Huei Liou,2 Yujun Li,1,3 Lu Gong,1 Yan Li,1 Yuan Hao,1 Betty Pham,1 Shuang Xu,1 Zhiqiang Jiang,1 Lijia Li,1 Yifan Peng,4 Dandi Qiao,1 Honghuang Lin,5 Pengda Liu,6 Wenyi Wei,7 Guo Zhang,8 Chih-Hao Lee,2 and Xiaobo Zhou1,9,*

SUMMARY

Obesity commonly co-exists with fatty liver disease with increasing health burden worldwide. Family with Sequence Similarity 13, Member A (FAM13A) has been associated with lipid levels and fat mass by genome-wide association studies (GWAS). However, the function of FAM13A in maintaining metabolic homeostasis in vivo remains unclear. Here, we demonstrated that rs2276936 in this locus has allelic-enhancer activity in massively parallel reporter assays (MPRA) and reporter assay. The DNA region containing rs2276936 regulates expression of endogenous FAM13A in HepG2 cells. In vivo, Fam13a−/− mice are protected from high-fat diet (HFD)-induced fatty liver accompanied by increased insulin sensitivity and reduced glucose production in liver. Mechanistically, loss of Fam13a led to the activation of AMP-activated protein kinase (AMPK) and increased mitochondrial respiration in primary hepatocytes. These findings demonstrate that FAM13A mediates obesity-related dysregulation of lipid and glucose homeostasis. Targeting FAM13A might be a promising treatment of obesity and fatty liver disease.

INTRODUCTION

Incidence of obesity and nonalcoholic fatty liver disease (NAFLD) has been increasing rapidly and is now the most common cause of chronic liver diseases worldwide (Younossi, 2019; Younossi et al., 2018). NAFLD may develop into nonalcoholic steatohepatitis and increase the risk of cardiovascular diseases and mortality; however, efficient treatment to block or slow down progression of NAFLD is still lacking (Lefere et al., 2019; Younossi et al., 2018). Genome-wide association studies (GWAS) have been instrumental to pinpoint important susceptible genes and possible therapeutic targets (Cannon and Mohlke, 2018) in complex traits. Genetic variants in the FAM13A (Family with Sequence Similarity 13, Member A) locus has been reported to be associated with HDL cholesterol and body mass index (BMI)-adjusted fasting insulin levels (Lundback et al., 2018; Willer et al., 2013), two relevant phenotypes for liver diseases. Furthermore, FAM13A locus has also been identified for its significant association with waist-to-hip ratio (WHR) adjusted for body mass index (WHRandBMI) (Shungin et al., 2015) and visceral to subcutaneous fat ratio (Ji et al., 2019).

Recently, FAM13A was reported to interact and stabilize IRS1 from degradation, thereby enhancing insulin signaling in adipocytes (Wardhana et al., 2018). In contrast, another group reported that Fam13a is dispensable for adipose development and insulin sensitivity in adipose tissue (Tang et al., 2019), suggesting complex regulation of glucose metabolism by FAM13A in adipose tissue. However, whether FAM13A regulates hepatic insulin sensitivity and lipid metabolism and their roles in fatty liver development are not explored yet.

In this study, we find that rs2276936 in the FAM13A locus, associated with multiple metabolic traits including HDL levels, demonstrated allelic enhancer activity. Furthermore, we find that Fam13a−/− mice showed improved hepatic insulin sensitivity and increased hepatic AMP-activated protein kinase (AMPK) activity, a major regulator in maintaining energy homeostasis and preventing against hepatic steatosis (Coughlan et al., 2014; Woods et al., 2017). These changes may collectively contribute to ameliorated high-fat diet (HFD)-induced obesity and nonalcoholic fatty liver in Fam13a−/− mice.

RESULTS

RS2276936 within FAM13A Gene Associated with HDL and Fat Mass Exerts Allelic Activity

Previously, we performed massively parallel reporter assays (MPRA) to assess allele-specific enhancer activity of SNPs within FAM13A GWAS locus (Castaldi et al., 2019) and identified 45 SNPs with significant
allelic effects. Given that the FAM13A locus associated with multiple metabolic traits including HDL levels, we further queried the association of these 45 MPRA SNPs with HDL levels using GWAS data from Global Lipids Genetics Consortium (Willer et al., 2013) (http://csg.sph.umich.edu/abecasis/public/lipids2013/). We found that three tightly correlated MPRA SNPs (r² > 0.9) demonstrated genome-wide (rs2276936, p < 10⁻⁸) or sub-genome-wide significance (rs2167750 and rs7695177, p < 10⁻⁵) of association with HDL levels (Table S1). Furthermore, these three SNPs are tightly correlated with previously published top GWAS SNPs associated with lipid traits including rs3822072 (Yaghootkar et al., 2016) and rs9991328 (Yaghootkar et al., 2016) (r² > 0.9 for all pairwise comparison). Major and minor haplotypes of these five SNPs comprised of >90% population of all ethnic groups (Machiela and Chanock, 2015, 2018) (Figure 1A). We also evaluated the association of these three SNPs, rs2276936, rs2167750, and rs7695177 with over 2000 complex traits from UK Biobank (Ge et al., 2017). They were associated with body fat distribution at genome-wide significance (p < 5 × 10⁻⁸) (Table S2).

Furthermore, we analyzed open chromatin status nearby three SNPs, rs2276936, rs2167750, and rs7695177 in primary human hepatic tissues and hepatocytes available from Roadmap epigenomics and ENCODE (encyclopedia of DNA elements) projects (Inoue et al., 2017; Kundaje et al., 2015). The DNA region nearby rs2276936 showed highest open chromatin scores among three SNPs, suggesting active regulatory element nearby this SNP in human liver tissues or cells (Figure 1B). To further investigate the regulatory effects of these three SNPs on the expression of FAM13A, we performed reporter assays by cloning the endogenous promoter of FAM13A gene and preceding SNP regions with one of two opposing alleles for each SNP into the luciferase constructs. The primers used for molecular cloning of reporter constructs are shown in Table S3. After transfection into HepG2 cells, rs2276936 demonstrated significant allelic effects (Figure 1B), with A-allele at forward orientation associated with higher luciferase activity. Furthermore, we engineered the CRISPR/Cas-9 constructs with either gRNA pairs to generate a 100bp deletion (Figure 1C) or a single gRNA to generate an indel (Figure 1D) spanning rs2276936. Sequence of gRNAs used for deletion generation nearby the rs2276936 is shown in Table S4. After transfection of these CRISPR constructs into HepG2 cells, we found that deletion of rs2276936 region led to 30% reduction in the expression of FAM13A, suggesting an enhancer activity of the DNA region spanning rs2276936.

Collectively, these data strongly suggested rs2276936 associated with HDL-regulated expression of FAM13A in an allele-specific manner with rs2276936C allele associated with lower enhancer activity in HepG2 cells.

Fam13a Deficiency Ameliorates HFD-induced Body Weight Gain

Given that FAM13A was associated with multiple metabolic phenotypes in GWAS, we investigated metabolic phenotypes of Fam13a knockout mice that we have previously generated (Jiang et al., 2016). Consistent with the previous report, Fam13a+/− mice demonstrated similar body weights, serum-free fatty acid levels, and triglycerides levels as compared with wild-type littermate control mice (Fam13a+/+) (Figures S1A–S1D) when fed on normal chow diet. However, total cholesterol levels are reduced in Fam13a+/− mice compared with Fam13a+/+ (Figure 1E), suggesting that Fam13a is required to maintain normal cholesterol levels.

HFD-treated mice chronically develop multiple metabolic changes, seen in fatty liver disease, an increasing global health burden (Perlemuter et al., 2007). To determine roles of FAM13A in this process, we treated mice with HFD for four months. In contrast to Fam13a+/− mice, Fam13a+/− mice demonstrated less body weight gain starting at two months of HFD treatment (Figures 2A and S2A) and increased lean mass and reduced fat mass after four months of HFD feeding (Figures 2B and S2B), likely attributable to decreased mass of inguinal fat (Figures 2C and S2C) rather than brown or epididymal fat (Figures S2E–S2H). Furthermore, liver mass is also reduced in HFD-treated Fam13a+/− mice (Figures 2D and S2D). However, oxygen consumption (VO2) (Figures S3A and S3B), energy expenditure (EE) (Figure S3C), respiratory exchange rate (Figure S3D), and food intake (Figure S3E) were comparable in Fam13a+/− mice and Fam13a+/+ mice after seven weeks of HFD treatment.

Fam13a+/− Mice Display Improved Hepatic Insulin Sensitivity and Reduced Hepatic Glucose Production

To assess glucose homeostasis, we performed glucose tolerance test (GTT) and insulin tolerance test (ITT) on Fam13a+/− mice and wild-type littermates after 14 weeks of HFD treatment. Despite similar fasting glucose levels (Figure S2I) and glucose tolerance (Figure 3A), Fam13a+/− mice demonstrated increased insulin sensitivity as suggested by ITT assay (Figure 3B), indicating that Fam13a deficiency sensitizes mice to
Figure 1. Identification of Functional Variants at the FAM13A Locus Associated with Lipid Levels

(A) LD matrix of SNPs (rs2276936, rs2167750, rs7695177) with previously frequently reported top GWAS SNPs (rs3822072 and rs9991328). The first two columns represent the major (red frame) and minor (blue frame) haplotypes of these five SNPs.

(B–D) (B) Top: the diagram shows the ATAC-Seq and DNase-Seq signals around SNP rs2276936, rs2167750, and rs7695177 in liver-relevant cell and tissues profiled by Roadmap epigenomics project and ENCODE project. Bottom: reporter assays of FAM13A promoter with or without DNA regions spanning rs2276936, rs2167750, and rs7695177 in HepG2 cells. For: forward orientation; Rev: reverse orientations. Data are presented as mean ± SEM from three biological replicates with triplicate wells in each repeat. *p < 0.05 by unpaired Student’s t test. Expression of FAM13A was assessed in HepG2 cells transfected with gRNA targeting rs2276936 for regional deletion (C) or indel deletion (D). Con: Control. Rs227-1 and rs227-2 are from two independent repeats. Data are presented as mean ± SEM from two biological replicates with triplicate wells in each repeat. *p < 0.05 by unpaired Student’s t test.
insulin response. However, we detected reduced insulin levels in serum from Fam13a/−/− mice (Figure 3C), indicating a plausible feedback due to increased insulin sensitivity.

Because liver is critical in systemic glucose homeostasis, we analyzed hepatic insulin signaling pathway via portal vein injection of insulin into HFD-fed Fam13a/−/− mice. Increased phosphorylation of Akt (p-Akt) (Thr308) was observed in Fam13a/−/− mice compared with Fam13a+/+ controls five minutes after insulin stimulation (Figure 3D). Furthermore, primary Fam13a/−/− hepatocytes also demonstrated increased levels of p-Akt after insulin treatment ex vivo compared with Fam13a+/+ cells (Figure 3E), suggesting increased hepatic insulin sensitivity in Fam13a/−/− hepatocytes. Additionally, hepatic glucose production was also significantly decreased in isolated primary Fam13a/−/− hepatocytes, compared with Fam13a+/+ cells (Figure 3F), suggesting that deficiency of Fam13a may lead to intrinsic reduction of gluconeogenesis in hepatocytes.

Partially consistent with recent findings that Fam13a may increase IRS-1 levels in white adipose tissues (Wardhana et al., 2018), we found a trend toward reduced levels of IRS-1 in epididymal fat (Figure S4A) whereas slightly increased IRS-1 levels in both inguinal fat (Figure S4B) and liver tissues (Figure S4C) compared with Fam13a+/+ control mice, suggesting that the regulation of Fam13a on insulin signaling in adipocytes is depot dependent.

**FAM13A Regulates Lipid Metabolism and Fam13a/−/− Mice Are Resistant to HFD-Induced Fatty Liver**

Given that the FAM13A locus is associated with HDL levels in GWAS, we also measured lipid levels in HFD-fed mice. Fam13a/−/− mice showed significantly reduced levels of LDL/VLDL and total cholesterol (Figure 4A) in
serum. Although levels of HDL (Figure 4A) and triglycerides (Figure S5A) in serum are comparable between Fam13a−/− and Fam13a+/+ mice, expression of the apolipoprotein A-I (Apoa1) gene that encodes major component of HDL was significantly increased in isolated hepatocytes (Figure 4B) and showed a trend toward increased levels in liver samples (Figure S5B) from Fam13a−/− mice compared with Fam13a+/+ littermates.

Chronic HFD treatment results in lipid accumulation in the liver, leading to fatty liver disease (Perlemuter et al., 2007). However, significantly lower levels of free fatty acid (Figure 4C), triglycerides (Figure 4D), and total cholesterol (Figure 4E) were detected in liver samples from Fam13a−/− mice compared with Fam13a+/+ control mice fed with HFD. We observed much less lipid accumulation in the livers of Fam13a−/− mice as compared with HFD-fed Fam13a+/+ mice (Figure 4F). Collectively, these data suggest that Fam13a deficiency ameliorates HFD-induced fatty liver. However, expression of inflammatory cytokines was comparable between these two genotypes (Figures SSC–S5I).

Figure 3. Fam13a−/− Mice Showed Improved Systemic and Hepatic Insulin Sensitivity after HFD Treatment

(A and B) (A) Glucose tolerance test (GTT) and (B) insulin tolerance test (ITT) were performed after overnight fasting or 6-h fasting in female Fam13a+/+ and Fam13a−/− mice fed with HFD for 14 weeks, respectively. (C) Serum insulin was measured in female Fam13a+/+ and Fam13a−/− mice fed with HFD for four months. (D) Immunoblotting of phosphorylation of Akt (Thr308) in liver from HFD-fed Fam13a+/+ and Fam13a−/− mice for four months with or without insulin injection via portal vein. Mice were harvested five minutes after insulin treatment. Mean ± SEM shown represent the densitometry of bands averaged from 3 to 4 mice/group. *p < 0.05 or **p < 0.01 by unpaired Student’s t test. (E) Akt phosphorylation at Thr308 was measured in primary hepatocytes cultured in the presence or absence of insulin at the concentration of 100 nM for 6 h. INS, insulin. (F) Hepatic glucose production was measured and normalized to total cellular protein amount in hepatocytes isolated from Fam13a+/+ and Fam13a−/− mice. (Mean ± SEM from three mice/genotypes). *p < 0.05, unpaired Student’s t test.
Increased Mitochondrial Function and Activation of the AMPK Signaling in Hepatocytes from Fam13a⁻/⁻ Mice

To determine the mechanism for improved fatty liver in Fam13a⁻/⁻ mice after HFD treatment, we assessed several possibilities including lipolysis, hepatic lipogenesis, mitochondrial function such as oxidative phosphorylation, and fatty acid oxidation in hepatocytes. First, lipolysis induced by injection of isoproterenol, a β3-adrenergic agonist, stimulated a significant increase of free fatty acid release in both Fam13a⁺/⁺ and Fam13a⁻/⁻ mice with negligible genotypic difference (Figure S6A). Secondly, expression of lipogenic genes including sterol regulatory element-binding transcription factor (Srebf1), a critical transcription factor to activate lipogenic gene (Hagiwara et al., 2012), and its target, fatty acid synthase (Fasn) (Radenne et al., 2008), were comparable in liver samples from Fam13a⁻/⁻ and Fam13a⁺/⁺ mice (Figures S6B and S6C).

Lastly, expression of critical genes for fatty acid β-oxidation, medium-chain acyl-coenzyme A dehydrogenase (Acadm), was increased in liver samples from HFD-fed Fam13a⁻/⁻ mice (Figure S6D), in contrast to carnitinepalmitoyltransferase 1A (Cpt1a) (Figure S6E).

We then assessed mitochondrial function in primary hepatocytes. Indeed, basal and maximal mitochondrial respiration were significantly increased in Fam13a⁻/⁻ hepatocytes, compared with Fam13a⁺/⁺.
hepatocytes as measured by Seahorse assay (Figures 5A and 5B), suggesting increased mitochondrial oxidative phosphorylation in primary hepatocytes under Fam13a deficiency. Consistently, expression of peroxisome proliferative activated receptor, gamma, coactivator 1 alpha (Ppargc1a), the master regulator of mitochondrial biogenesis and oxidative phosphorylation (Jun et al., 2014), is increased in Fam13a−/− hepatocytes, compared with Fam13a+/+ hepatocytes (Figure 5F).

Furthermore, we determined the activity of AMPK, a critical regulator in energy homeostasis, in Fam13a−/− liver samples. Accompanied by improved fatty liver in Fam13a−/− mice, AMPK activation as indicated by phosphorylation of AMPK (Thr172) was significantly enhanced in liver from Fam13a−/− mice fed with HFD (Figure 5C). Increased activation of AMPK was also detected in primary hepatocytes from Fam13a−/− mice fed on normal chow, suggesting an intrinsic inhibition on AMPK in hepatocytes by FAM13A (Figure 5D). This was further confirmed by increased AMPK activation detected in HepG2 cells transfected with FAM13A siRNA (Figure 5E). These data indicate that deficiency of Fam13a led to hepatic activation of AMPK pathway that may contribute to less body weight gain and ameliorated fatty liver in Fam13a−/− mice under HFD treatment.
FAM13A Regulates Mitochondrial Function through AMPK Signaling

Furthermore, overexpression of FAM13A reduced basal and maximal mitochondrial respiration, and ATP production (Figure 6A), accompanied by decreased phosphorylation level of AMPK (Thr172) (Figure 6B) in HepG2 cells. To determine whether FAM13A regulates mitochondrial function through AMPK, stable knockdown of FAM13A was established in HepG2 cells by shRNA targeting AMPKα and/or FAM13A, as opposed to scramble RNA control. Although knockdown of FAM13A led to increased mitochondrial respiration (Figures 6C–6E), this was abolished by silencing of AMPK. Taken together, these data suggest that FAM13A regulates mitochondrial function through dephosphorylation and inactivation of AMPK and thus possibly promotes lipid accumulation in hepatic cells (Figure 7A).

DISCUSSION

Our current studies provided in vivo and in vitro evidence supporting important roles of FAM13A, a gene consistently associated with multiple metabolic phenotypes in GWAS, in regulating hepatic glucose and lipid metabolism. By reporter and CRISPR/Cas-9 assays, we pinpointed rs2276936 as the possible functional variant regulating hepatic FAM13A expression. Furthermore, we demonstrated that Fam13a<sup>−/−</sup> mice are protected from HFD-induced fatty liver and lipid toxicity with improved hepatic insulin sensitivity. Increased AMPK activation associated with increased mitochondrial respiration was detected in hepatocytes from Fam13a<sup>−/−</sup> mice, which likely contributes to ameliorated HFD-induced fatty liver in Fam13a<sup>−/−</sup> mice. Importantly, most of the directional effects of risk allele rs2276936C were recapitulated in knockout mouse model, such as fat mass, insulin sensitivity, and total cholesterol levels (Figure 7B). Admittedly, some of human GWAS traits were not confirmed with genotypic difference in mouse models such as HDL levels, further highlighting the complexity of using mouse model to recapitulate human GWAS findings (Small et al., 2018).

From GWAS to Function

Identification of functional variants in the GWAS locus is the crucial and necessary first step to translate genetic discoveries to disease understanding and ultimately, therapy. The FAM13A locus has been associated with BMI-adjusted fasting insulin level (Lundback et al., 2018), HDL level (Willer et al., 2013), and waist-to-hip ratio (Shungin et al., 2015) in GWAS in multiple replicated studies. However, functional variants in this region and function of FAM13A gene in regulating metabolism in vivo remain incompletely understood yet. Here, we identified rs2276936 with allelic enhancer activities is located in the first intron of FAM13A, about ~18kb away from its transcription start site. Interestingly, this SNP is also located nearby multiple enhancer marks including H3K4Me1, H3K27Ac, and H3K9Ac as well as DNase hypersensitive sites in liver, suggesting regulatory function of rs2276936. We primarily focused on roles of rs2276936 in liver here, given the importance of liver in regulating HDL, lipid, and glucose metabolism. Further investigations are warranted to determine roles of rs2276936 in adipose tissue and other metabolic active tissues. It is not surprising that pleiotropic functional variants may have effects on multiple tissues. For example, the significant BMI GWAS SNPs in the fat mass and obesity-associated (FTO) locus may regulate Iroquois homeobox 3 (Irx3) and Iroquois homeobox 5 (Irx5), the major causal genes (Smemo et al., 2014), in both brain (Smemo et al., 2014) and adipose tissues (Claussnitzer et al., 2015). Functional variants regulating lipid GWAS gene sortilin 1 (Sort1) demonstrated greater allelic effects in the liver sample (Musunuru et al., 2010) despite abundant expression of Sort1 in adipose tissues. These examples highlight the challenges and complexity of functional variants identification in GWAS loci in effect cell types.

It is noteworthy that rs2276936C, tightly correlated with previous top GWAS SNP rs9991328T (Figure 1A), is associated with reduced fat mass in human subjects (Table S2) and reduced enhancer activity for Fam13A (Figure 1B), which is consistent with reduced body and fat weight in Fam13a<sup>−/−</sup> mice (Figures 2A and 2C) in mouse models as we summarized in Figure 7.

Insulin Sensitivity in Fam13a<sup>−/−</sup> Mice

Through ITT measurements, we observed increased insulin sensitivity in Fam13a<sup>−/−</sup> mice than Fam13a<sup>+/+</sup> mice fed with HFD. However, no glucose tolerance difference was detected by GTT assay. This may result from compensatory reduction of insulin levels in Fam13a<sup>−/−</sup> mice (Figure 3C).

Hepatic glucose production is also crucial for maintaining glucose homeostasis that is mainly controlled by gluconeogenesis through insulin and glucagon pathways. Reduced hepatic glucose production may result
from increased insulin sensitivity in Fam13a−/− hepatocytes through inhibition on the gluconeogenesis by insulin. Given that increased insulin sensitivity upon Fam13a deficiency was detected in primary hepatocytes isolated from normal chow- and HFD-fed mice, FAM13A likely intrinsically inhibits hepatic insulin sensitivity. In contrast, the regulation of FAM13A on insulin sensitivity in adipose tissues seems more complex depending on the depots of white adipose tissue, which may explain previously inconsistent results.
ranging from reduced (Wardhana et al., 2018) to similar (Tang et al., 2019) insulin sensitivity in adipose tissues from Fam13a/C0/C0 mice fed with HFD. We found variable changes of IRS-1 in different types of adipose tissues from Fam13a/C0/C0 mice with a trend toward decreased levels of IRS-1 in epididymal fat (Figure S4A), similar as previously reported (Wardhana et al., 2018), whereas slightly increased IRS-1 levels in inguinal fat (Figure S4B). Other reasons for some of the discrepancies between two previous studies and ours may include differences in the composition of diet, HFD treatment age and duration, genetic backgrounds of Fam13a/C0/C0 mice, and technical details, which may complicate results interpretation. For example, an HFD containing 35% fat, 25.3% carbohydrates, and 23% protein was used previously to feed six-week-old Fam13a/C0/C0 mice (C57BL/6N background) for 14 weeks compared with wild-type C57BL/6N mice in the studies (Wardhana et al., 2018). Herein, four- to five-month-old Fam13a/C0/C0 mice after three generations of backcrossing toward C57BL/6J background and Fam13a+/+ littermates were fed with HFD containing 36% fat, 35.7% carbohydrates, and 20.5% protein for four months. Furthermore, previous ITT assay was performed in mice without fasting (Wardhana et al., 2018), in contrast to our ITT assay with mice after 6 h of fasting. Therefore, experimental condition is critical to interpret metabolic phenotypes in mice, and more stringently controlled studies are required to elucidate how FAM13A modulates insulin sensitivity in the adipose tissue.

**Ameliorated Fatty Liver and Increased AMPK Activation in the Fam13a/C0/C0 Mice**

Insulin sensitivity, body weight gain, and fatty liver can influence each other. Reduced body weight can possibly improve fatty liver and insulin resistance, whereas HFD-induced hepatic insulin resistance may lead to fatty liver due to failed inhibition on gluconeogenesis combined with selectively enhanced lipogenesis in liver by insulin (Petersen et al., 2017). In the present study, given reduced gluconeogenesis was found...

**Figure 7. Schematic Illustration of FAM13A Regulating lipid and Glucose Metabolism**
(A) Mechanism of FAM13A regulating Hepatic steatosis and insulin resistance through AMPK. TG: triglycerides. HFD: high-fat diet.
(B) Metabolic phenotypes observed in human subjects with opposing genotypes for SNP rs2276936 and Fam13a/C0/C0 mice (Ji et al., 2019).
in isolated primary hepatocytes from Fam13a−/− mice, it is likely ameliorated fatty liver resulted from improved hepatic insulin sensitivity. Furthermore, in HFD-fed Fam13a−/− mice, despite increased hepatic insulin sensitivity, improved fatty liver was found without significantly increased lipogenesis by insulin pathway, possibly due to hepatic activation of AMPK. Admittedly, future studies using liver-specific Fam13a−/− mice will be helpful to conclusively exclude the possibility of improved fatty liver resulting from less body weight gain in Fam13a−/− mice.

AMPK is activated by reduced ATP/AMP ratio due to prolonged energy deprivation, thus facilitating utilization of various sources of nutrients to generate ATP. Consequently, upon AMPK activation, ATP-consuming pathways, including cholesterol and fatty acid synthesis, are repressed and ATP-generating pathways, including fatty acid oxidation and lipolysis, are activated (Woods et al., 2017) through regulatory enzymes or regulatory proteins involved in anabolic pathways (Hardie et al., 2012). For example, AMPK represses cholesterol synthesis by inhibiting sterol regulatory element-binding factor 2 (Srebf2) and hydroxymethylglutaryl-CoA (HMG-CoA) reductase (Li et al., 2011). Therefore, activation of AMPK in primary hepatocytes isolated from Fam13a−/− mice may explain reduced cholesterol levels in serum from Fam13a−/− mice fed with normal chow (Figure S1E). Furthermore, increased mitochondrial respiration in primary Fam13a−/− hepatocytes is also consistent with enhanced expression of Ppargc1α, a key gene essential for mitochondrial synthesis and regulated by AMPK (Hardie et al., 2012).

AMPK was recently suggested as a therapeutic target for the treatment of obesity, fatty liver disease (Garcia et al., 2019), and type 2 diabetes (Coughlan et al., 2014) due to its importance as a master regulator in maintaining glucose and lipid homeostasis. For example, genetic or pharmacological activation of AMPK in murine livers decreased lipogenesis, ameliorated high-fructose-induced hepatic triglyceride accumulation and thus improved hepatic steatosis (Woods et al., 2017), similar as we observed in HFD-fed Fam13a−/− mice. Notably, hepatic activation of AMPK by overexpression of truncated AMPKα1 induced by doxycycline treatment improved HFD-induced weight gain and white fat depot accumulation, even after obesity and fatty liver disease have been established (Garcia et al., 2019). In addition, such hepatic activation of AMPK usually does not reduce levels of blood glucose (Cokorinos et al., 2017; Woods et al., 2017), as we observed as well (Figure S2I). Admittedly, hepatic role of AMPK activation in regulating body weight gain is far more complex. Despite knockin of activating mutations in the AMPKα2 subunit reduced fat mass and liver steatosis upon diet-induced obesity (Yang et al., 2016), liver-specific constitutive activation of AMPK protected mice against only high-fructose diet-induced liver steatosis (Woods et al., 2017), in contrast to HFD treatment.

It is likely that hepatic activation of AMPK pathway may not explain all the metabolic phenotypes that we observed in Fam13a−/− mice, and future studies using hepatocyte-specific and/or adipocyte-specific Fam13a knockout mice may help explain the pleotropic regulation of FAM13A on glucose and lipid metabolism. Nonetheless, our study provides several lines of evidence to reveal that a common DNA variant rs2276936 associated with four metabolic traits regulates hepatic expression of FAM13A. Fam13a−/− mice are protected from HFD-induced weight gain, hepatic lipid accumulation, and insulin resistance, possibly by increasing the AMPK activity. More importantly, in human subjects, FAM13A locus is associated with lipid metabolism and insulin sensitivity and increased expression of FAM13A was found in liver cirrhosis tissues compared with normal liver samples (Zhang et al., 2019). Given protective effects of Fam13a deficiency in diet-induced fatty liver, our results suggest FAM13A as a possible interventional target for the treatment of obesity and fatty liver disease.

**Limitations of the Study**

We demonstrated that deficiency of FAM13A protected mice from HFD-induced obesity and fatty liver using a global Fam13a knockout mouse line. To conclusively determine whether FAM13A deficiency in liver or fat contributes to ameliorated body weight gain and lipid accumulation in liver after HFD treatment, future studies with hepatocyte-specific Fam13a−/− mice and adipose-specific Fam13a−/− mice are warranted. Secondly, despite phosphorylation of AMPK at Thr172 has been widely used to indicate AMPK activity, future more comprehensive evaluation on AMPK activity measured by AMPK activity kits including tissue-specific regulation of AMPK by FAM13A would strengthen our findings. Lastly, future work will also include testing the silencing of Fam13a as a possible treatment strategy in diet-induced obesity and fatty liver mouse models.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100928.

ACKNOWLEDGEMENTS
This work was supported by National Institutes of Health (NIH) grants: R01HL127200, R01HL137927 and R33 HL120794 to X. Z. and R01DK113791 and R21AI131659 to C.H.L.

AUTHOR CONTRIBUTIONS
X.Z., C.H.L., and X.L designed the study. Y.L., X.L., and L.G. performed Seahorse assay. X.L., X.Z., and G.Z. performed data analysis. X.L., Y.L., and Y.P. did Western blot and Immunoprecipitation. X.L. and S.X. performed and analyzed animal experiments. Y.H.L. and X.L. isolated primary hepatocytes and performed cell experiments in primary hepatocytes. W.W. and Z.J. provided plasmids. B.P., Y.H., Y.L., and L.L. performed real-time PCR. X.L., X.Z., P.L., W.W., G.Z., and C.H.L. wrote the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: January 15, 2020
Accepted: February 17, 2020
Published: March 27, 2020

REFERENCES
Cannon, M.E., and Mohlke, K.L. (2018). Deciphering the emerging complexities of molecular mechanisms at GWAS loci. Am. J. Hum. Genet. 102, 637–653.

Castaldi, P.J., Guo, F., Qiao, D., Du, F., Naing, Z.Z.C., Li, Y., Pham, B., Mikkelsen, T.S., Cho, M.H., Silverman, E.K., et al. (2019). Identification of functional variants in the FAM13A chronic obstructive pulmonary disease genome-wide association study locus by massively parallel reporter assays. Am. J. Respir. Crit. Care Med. 199, 52–61.

Clausnitzer, M., Dankel, S.N., Kim, K.H., Quon, G., Meuleman, W., Haugen, C., Glunk, V., Sousa, I.S., Beaudry, J.L., Puvvindran, V., et al. (2015). FTO obesity variant circuitry and adipocyte browning in humans. N. Engl. J. Med. 373, 895–907.

Cokroinos, E.C., Delmore, J., Reyes, A.R., Albuquerque, B., Kjolsted, R., Jorgensen, N.O., Tran, J.L., Jakar, A., Cialdea, K., Esquejo, R.M., et al. (2017). Activation of skeletal muscle AMPK promotes glucose disposal and glucose lowering in non-obese primates and mice. Cell Metab. 25, 1147–1159.e10.

Coughlan, K.A., Valentine, R.J., Ruderman, N.B., and Saha, A.K. (2014). AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab. Syndr. Obes. 7, 241–253.

Garcia, D., Hellberg, K., Chaix, A., Wallace, M., Herzog, S., Badur, M.G., Lin, T., Shokhirev, M.N., Pinto, A.F.M., Ross, D.S., et al. (2019). Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD. Cell Rep. 26, 192–208.e196.

Ge, T., Chen, C.Y., Neale, B.M., Sabuncu, M.R., and Smoller, J.W. (2017). Phenome-wide heritability analysis of the UK Biobank. PLoS Genet. 13, e1006711.

Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M.H., Ruegg, M.A., and Hall, M.N. (2012). Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokonase, and SREBP1c. Cell Metab. 15, 725–738.

Hardie, D.G., Ross, F.A., and Hawley, S.A. (2012). AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251–262.

Inoue, F., Kircher, M., Martin, B., Cooper, G.M., Witten, D.M., McManus, M.T., Ahituv, N., and Shendure, J. (2017). A systematic comparison reveals substantial differences in chromosomal versus episomal encoding of enhancer activity. Genome Res. 27, 38–52.

Ji, Y., Yokars, A.M., Frau, F., Mook-Kanamori, D., Staiger, H., Thomas, E.L., Atabaki-Pasdar, N., Campbell, A., Tyrell, J., Jones, S.E., et al. (2019). Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension. Diabetes 68, 207–219.

Jiang, Z., Lao, T., Qiu, W., Polverino, F., Gupta, K., Guo, F., Mancini, J.D., Naing, Z.Z., Cho, M.H., Castaldi, P.J., et al. (2016). A chronic obstructive pulmonary disease susceptibility gene, FAM13A, regulates protein stability of beta-catenin. Am. J. Respir. Crit. Care Med. 194, 185–197.

Jun, H.J., Joshi, Y., Patil, Y., Noland, R.C., and Chang, J.S. (2014). NT-POC-Talpia activation attenuates high-fat diet-induced obesity by enhancing brown fat thermogenesis and adipose tissue oxidative metabolism. Diabetes 63, 3615–3625.

Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., Ziller, M.J., et al. (2015). Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330.

Lefere, S., Van de Velde, F., Hoorens, A., Raevens, S., Van Campenhout, S., Vandierendonck, A., Neyt, S., Vandeghinste, B., Vanhoove, C., Debbaut, C., et al. (2019). Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease. Hepatology 69, 1087–1104.

Li, Y., Xu, S., Mihaylova, M.M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., Lefai, E., Shyy, J.Y., et al. (2011). AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13, 376–388.

Lundback, V., Kulyte, A., Strawbridge, R.J., Ryden, M., Arner, P., Marcus, C., and Dahlman, I. (2018). FAM13A and POM121C are candidate genes for fasting insulin: functional follow-up analysis of a genome-wide association study. Diabetologia 61, 1112–1123.
Machiela, M.J., and Chanock, S.J. (2015). LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31, 3555–3557.

Machiela, M.J., and Chanock, S.J. (2018). LDassoc: an online tool for interactively exploring genome-wide association study results and prioritizing variants for functional investigation. Bioinformatics 34, 887–889.

Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N.E., Ahefelt, T., Sachs, K.V., Li, X., Li, H., Kuperwasser, N., Ruda, V.M., et al. (2010). From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466, 714–719.

Perlemuter, G., Bigorgne, A., Cassard-Doulcier, A.M., and Naveau, S. (2007). Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat. Clin. Pract. Endocrinol. Metab. 3, 458–469.

Petersen, M.C., Vatner, D.F., and Shulman, G.I. (2017). Regulation of hepatic glucose metabolism in health and disease. Nat. Rev. Endocrinol. 13, 572–587.

Radenne, A., Akpa, M., Martel, C., Sawadogo, S., Mauvoisin, D., and Mourier, C. (2008). Hepatic regulation of fatty acid synthase by insulin and T3: evidence for T3 genomic and nongenomic actions. Am. J. Physiol. Endocrinol. Metab. 295, E884–E894.

Shungin, D., Winkler, T.W., Croteau-Chonka, D.C., Ferreira, T., Locke, A.E., Magi, R., Strawbridge, R.J., Pers, T.H., Fischer, K., Justice, A.E., et al. (2015). New genetic loci link adipose and insulin biology to body fat distribution. Nature 578, 187–196.

Small, K.S., Todorcevic, M., Civilek, M., El-Sayed-Moustafa, J.S., Wang, X., Simon, M.M., Fernandez-Tajes, J., Mahajan, A., Honkoki, M., Hugill, A., et al. (2018). Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on adipocyte size and body composition. Nat. Genet. 50, 572–580.

Smemo, S., Tena, J.J., Kim, K.H., Gamazon, E.R., Sakabe, N.J., Gomez-Marín, C., Aneas, I., Credidio, F.L., Sobreira, D.R., Wasserman, N.F., et al. (2014). Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature 507, 371–375.

Tang, J., Zhou, H., Sahay, K., Xu, W., Yang, J., Zhang, W., and Chen, W. (2019). Obesity-associated family with sequence similarity 13 member A (FAM13A) is dispensable for adipose development and insulin sensitivity. Int. J. Obes. (Lond.) 43, 1269–1280.

Wardhana, D.A., Ikeda, K., Barinda, A.J., Nugroho, D.B., Qurania, K.R., Yagi, K., Miyata, K., Oike, Y., Hiraishi, K.I., and Emoto, N. (2018). Family with sequence similarity 13 member A modulates adipocyte insulin signaling and preserves systemic metabolic homeostasis. Proc. Natl. Acad. Sci. U S A 115, 1529–1534.

Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., Buchkovich, M.L., Mora, S., et al. (2013). Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274–1283.

Woods, A., Williams, J.R., Muckett, P.J., Mayer, F.V., Liljedahl, M., Bohlooly, Y.M., and Carling, D. (2017). Liver-specific activation of AMPK prevents steatosis on a high-fructose diet. Cell Rep. 18, 3043–3051.

Yaghootkar, H., Lotta, L.A., Tyrrell, J., Smit, R.A., Jones, S.E., Donnelly, L., Beaumont, R., Campbell, A., Tuke, M.A., Hayward, C., et al. (2016). Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension, and heart disease. Diabetes 65, 2448–2460.

Yang, X., Mudgett, J., Bou-About, G., Champy, M.F., Jacobs, H., Monassier, L., Pavlovic, G., Song, T., Herault, Y., Petit-Demouliere, B., et al. (2016). Physiological expression of AMPKgama2RG mutation causes Wolff-Parkinson-White syndrome and induces kidney injury in mice. J. Biol. Chem. 291, 23428–23439.

Younossi, Z.M. (2019). Non-alcoholic fatty liver disease - a global public health perspective. J. Hepatol. 70, 531–544.

Younossi, Z.M., Loomba, R., Runia, M.E., Bugianesi, E., Marchesini, G., Neuschwander-Tetri, B.A., Serfaty, L., Negro, F., Caldwell, S.H., Ratsuz, V., et al. (2018). Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 68, 361–371.

Zhang, Y., Wang, S., Wang, C., Xiao, J., Zhang, S., and Zhou, H. (2019). High expression of FAM13A was associated with increasing the liver cirrhosis risk. Mol. Genet. Genomic Med. 7, e543.
Supplemental Information

FAM13A Represses AMPK Activity and Regulates Hepatic Glucose and Lipid Metabolism

Xin Lin, Yae-Huei Liou, Yujun Li, Lu Gong, Yan Li, Yuan Hao, Betty Pham, Shuang Xu, Zhiqiang Jiang, Lijia Li, Yifan Peng, Dandi Qiao, Honghuang Lin, Pengda Liu, Wenyi Wei, Guo Zhang, Chih-Hao Lee, and Xiaobo Zhou
Figure S1. *Fam13a*–/– mice showed similar metabolic homeostasis in normal chow-fed female mice. Related to Figure 2.

Body weight gain of mice (A) and actual body weight (B) in normal chow-fed *Fam13a*+/+ and *Fam13a*–/– mice for 3 months. Body weight was monitored every week from 8 weeks of age (n = 5-7 mice per group). Free fatty acid (C), triglycerides (D) and cholesterol (E) levels in *Fam13a*+/+ and *Fam13a*–/– mice were assessed in serum from mice fasted overnight. Data are presented as mean ± SEM from 5-7 mice per genotype. *p < 0.05 by unpaired Student’s t-test.
Figure S2. *Fam13a*−/− mice showed reduced body weight after high fat diet (HFD) treatment for 4 months. Related to Figure 2 and 3.

(A) Body weight was measured during HFD treatment for 4 months in *Fam13a*+/+(n = 13) and *Fam13a*−/− mice (n = 11). (B) Fat and lean mass of mice (A) measured by MRI after 4 months of HFD treatment. Weight of inguinal fat (C) and liver (D) in mice treated with HFD (n = 6 for *Fam13a*+/+; n = 5 for *Fam13a*−/−). Brown fat (E) and epididymal fat (G) mass normalized to body weight in mice treated with HFD. Weight of brown fat (F) and epididymal fat (H) were assessed with HFD-fed mice for 4 months (n = 6 for *Fam13a*+/+; n = 5 for *Fam13a*−/−). (I) Blood glucose was measured after fasting overnight in mice treated with HFD for 14 weeks (n = 6 for *Fam13a*+/+; n = 5 for *Fam13a*−/−). Data are presented as mean ± SEM. *p < 0.05 by unpaired Student’s t-test. HFD: high fat diet.
Figure S3. Metabolic cage measurements in Fam13a<sup>−/−</sup> mice after HFD treatment for 7 weeks. Related to Figure 2.

Oxygen consumption (A and B), energy expenditure (C), respiratory exchange rate (D) and food intake (E) were analyzed in Fam13a<sup>+/+</sup> and Fam13a<sup>−/−</sup> mice (n = 6 mice/genotype). Data are presented as mean ± SEM. HFD: high fat diet; VO2: oxygen consumption; EE: energy expenditure.
Figure S4. Protein levels of IRS-1 was determined by immunoblotting in epididymal fat (A), inguinal fat (B) and liver (C) from HFD-fed Fam13a+/+ and Fam13a−/− mice for 4 months. Related to Figure 3. Quantifications were shown on the right with mean ± SEM from 4-6 mice per group. *p < 0.05 or **p < 0.01 by unpaired Student’s t-test. HFD: high fat diet.
Figure S5. Triglycerides and gene expression measurements in the liver samples from HFD-fed Fam13a<sup>+/+</sup> and Fam13a<sup>-/-</sup> mice for 4 months. Related to Figure 4.
(A) Triglycerides levels were determined in serum from HFD-fed Fam13a<sup>+/+</sup> and Fam13a<sup>-/-</sup> mice. Expression of Apoa1 (B), IFN-γ (C), MMP9 (D), IL-10 (E), TNF (F), IL-1β (G), F4/80 (H) and IL-6 (I) were assessed by real-time PCR. Data are presented as mean ± SEM from 5-6 mice per group. HFD: high fat diet.
Figure S6. Regulation of lipolysis and oxidative metabolism in Fam13a<sup>+/+</sup> and Fam13a<sup>-/-</sup> mice. Related to Figure 5.

(A) Free fatty acid was measured in serum from normal chow-fed Fam13a<sup>+/+</sup> and Fam13a<sup>-/-</sup> female mice with or without isoproterenol-, a β3-adrenergic receptor agonist. Data are presented as mean ± SEM from 6 mice per group. *p < 0.05 vs. no ISO by two-way ANOVA. ISO: isoproterenol. mRNA levels of Srebf1 (B), Fasn (C), Acadm (D) and Cpt1a (E) were determined in the liver tissues from HFD-fed Fam13a<sup>+/+</sup> and Fam13a<sup>-/-</sup> mice for 4 months. (n = 6 for Fam13a<sup>+/+</sup>; n = 5 for Fam13a<sup>-/-</sup>). (F) Expression of Ppargc1α from primary hepatocytes was shown. Data are presented as mean ± SEM. *p < 0.05 by unpaired Student’s t-test. HFD: high fat diet.
Table S1. Association of MPRA SNPs in the FAM13A GWAS locus with HDL level. Related to Figure 1. Three SNPs shown significant association at genome-wide levels were indicated by bold.

| Chr Pos       | SNP      | A1 | A2 | beta | N    | HDL P-value | Freq.A1.1000G.EUR |
|---------------|----------|----|----|------|------|-------------|-------------------|
| chr4:89726283 | rs2276936| a  | c  | 0.022| 181105| 9.6E-10     | 0.5               |
| chr4:89726283 | rs2276936| a  | c  | 0.022| 181105| 9.6E-10     | 0.5               |
| chr4:89737558 | rs7695177| c  | g  | 0.023| 94311 | 3.04E-06    | NA                |
| chr4:89737558 | rs7695177| c  | g  | 0.023| 94311 | 3.04E-06    | NA                |
| chr4:89730074 | rs2167750| c  | t  | 0.022| 94311 | 5.19E-06    | 0.504             |
| chr4:89730074 | rs2167750| c  | t  | 0.022| 94311 | 5.19E-06    | 0.504             |
| chr4:89730074 | rs2167750| c  | t  | 0.022| 94311 | 5.19E-06    | 0.504             |
| chr4:89734587 | rs1350506| t  | c  | 0.022| 94311 | 0.000103    | 0.5013            |
| chr4:89885086 | rs2013701| g  | t  | 0.009| 91319 | 0.08229     | 0.5               |
| chr4:89885086 | rs2013701| g  | t  | 0.009| 91319 | 0.08229     | 0.5               |
| chr4:89885086 | rs2013701| g  | t  | 0.009| 91319 | 0.08229     | 0.5               |
| chr4:89885086 | rs2013701| g  | t  | 0.009| 91319 | 0.08229     | 0.5               |
| chr4:89885086 | rs2013701| g  | t  | 0.009| 91319 | 0.08229     | 0.5               |
| chr4:89885086 | rs2013701| g  | t  | 0.009| 91319 | 0.08229     | 0.5               |
| chr4:89883979 | rs7671167| c  | t  | 0.009| 91319 | 0.08721     | 0.4987            |
| chr4:89883979 | rs7671167| c  | t  | 0.009| 91319 | 0.08721     | 0.4987            |
| chr4:89883979 | rs7671167| c  | t  | 0.009| 91319 | 0.08721     | 0.4987            |
| chr4:89986326 | rs6857969| a  | g  | 0.006| 94311 | 0.2168      | 0.3404            |
| chr4:89986326 | rs6857969| a  | g  | 0.006| 94311 | 0.2168      | 0.3404            |
| chr4:89986326 | rs6857969| a  | g  | 0.006| 94311 | 0.2168      | 0.3404            |
| chr4:89998258 | rs874147 | a  | c  | 0.006| 91202 | 0.229       | 0.3443            |
| chr4:89930313 | rs1795739| g  | a  | 0.004| 91319 | 0.3556      | 0.6161            |
| chr4:89930313 | rs1795739| g  | a  | 0.004| 91319 | 0.3556      | 0.6161            |
| chr4:90036099 | rs12645173| g | a  | 0.006| 94311 | 0.4808     | 0.3575            |
| chr4:89921981 | rs7656238| t  | c  | 0.004| 94311 | 0.4848     | 0.7863            |
| chr4:89918968 | rs10516826| c | t  | 0.005| 94311 | 0.5262     | 0.8285            |
| chr4:90077431 | rs7672894| t  | a  | 0.002| 94311 | 0.604      | 1                 |
| chr4:90077431 | rs7672894| t  | a  | 0.002| 94311 | 0.604      | 1                 |
| chr4:90077431 | rs7672894| t  | a  | 0.002| 94311 | 0.604      | 1                 |
| chr4:90077431 | rs7672894| t  | a  | 0.002| 94311 | 0.604      | 1                 |
| chr4:90077431 | rs7672894| t  | a  | 0.002| 94311 | 0.604      | 1                 |
| Chr:Pos | SNP      | A1 | A2 | Freq.A1.1000G.EUR | N: Subject number |
|---------|----------|----|----|-------------------|-------------------|
| chr4:89919413 | rs2869972 | a  | g  | 0.003             | 94311             | 0.6438  | 0.7863 |
| chr4:90059434  | rs6828137 | g  | t  | 0.003             | 94291             | 0.7704  | 0.5435 |
| chr4:89930434  | rs1795738 | t  | c  | 0.002             | 94288             | 0.7948  | 0.7916 |
| chr4:89727979  | rs10516821| c  | t  | 8E-04             | 71228             | 0.8077  | 0.05937|
| chr4:89854079  | rs4693977 | t  | a  | 9E-04             | 94311             | 0.8814  | 1      |
| chr4:89973910  | rs2670623 | a  | g  | 9E-04             | 94311             | 0.8974  | 0.8021 |
| chr4:89938362  | rs12508524| a  | g  | 3E-04             | 94283             | 0.9125  | 0.2876 |

Chr Pos: Chromosome position of a given variant.
SNP: Single nucleotide polymorphism.
A1 and A2: two opposing alleles for each given variant.
Freq.A1.1000G.EUR: Allele frequency of the major allele for each variant
N: Subject number for each genotype of a given variant.
Table S2. Association of three significant HDL and MPRA SNPs near FAM13A gene with body fat distribution and whole-body fat mass in subjects from UK Biobank. Related to Figure 1.

| SNP       | Trait                                      | P-value    | Beta      | N Overall | Variant          | Effect allele |
|-----------|--------------------------------------------|------------|-----------|-----------|------------------|---------------|
| rs2167750 | Body fat percentage                        | 1.32E-12   | -0.0132542| 331117    | 4_89730074_C_T   | T             |
| rs2167750 | Impedance of arm (right)                   | 1.58E-12   | -0.012114 | 331279    | 4_89730074_C_T   | T             |
| rs2167750 | Hip circumference                          | 1.90E-12   | -0.0169994| 336601    | 4_89730074_C_T   | T             |
| rs2167750 | Arm fat percentage (left)                  | 5.82E-11   | -0.0120825| 331198    | 4_89730074_C_T   | T             |
| rs2167750 | Trunk fat mass                             | 6.32E-10   | -0.0151724| 331093    | 4_89730074_C_T   | T             |
| rs2167750 | Arm fat percentage (right)                 | 1.02E-09   | -0.0113193| 331249    | 4_89730074_C_T   | T             |
| rs2167750 | Whole body fat mass                        | 1.49E-08   | -0.0134662| 330762    | 4_89730074_C_T   | T             |
| rs2276936 | Trunk fat percentage                       | 1.43E-13   | -0.0165482| 331113    | 4_89726283_A_C   | C             |
| rs2276936 | Impedance of arm (left)                    | 5.22E-13   | -0.0124158| 331292    | 4_89726283_A_C   | C             |
| rs2276936 | Hip circumference                          | 2.44E-12   | -0.0168992| 336601    | 4_89726283_A_C   | C             |
| rs2276936 | Body fat percentage                        | 2.53E-12   | -0.013072 | 331117    | 4_89726283_A_C   | C             |
| rs2276936 | Impedance of arm (right)                   | 7.39E-12   | -0.0117307| 331279    | 4_89726283_A_C   | C             |
| rs2276936 | Arm fat percentage (left)                  | 7.33E-11   | -0.0120074| 331198    | 4_89726283_A_C   | C             |
| rs2276936 | Arm fat percentage (right)                 | 8.99E-10   | -0.0113457| 331249    | 4_89726283_A_C   | C             |
| rs2276936 | Trunk fat mass                             | 9.69E-10   | -0.0149921| 331093    | 4_89726283_A_C   | C             |
| rs2276936 | Whole body fat mass                        | 1.77E-08   | -0.0133836| 330762    | 4_89726283_A_C   | C             |
| rs7695177 | Trunk fat percentage                       | 2.04E-13   | -0.0164525| 331113    | 4_89737558_C_G   | G             |
| rs7695177 | Hip circumference                          | 1.82E-12   | -0.017008 | 336601    | 4_89737558_C_G   | G             |
| rs7695177 | Impedance of arm (left)                    | 2.66E-12   | -0.0120368| 331292    | 4_89737558_C_G   | G             |
| rs7695177 | Body fat percentage                        | 3.98E-12   | -0.0129615| 331117    | 4_89737558_C_G   | G             |
| rs7695177 | Impedance of arm (right)                   | 2.18E-11   | -0.01477  | 331279    | 4_89737558_C_G   | G             |
| rs7695177 | Arm fat percentage (left)                  | 9.11E-11   | -0.0119544| 331198    | 4_89737558_C_G   | G             |
| rs7695177 | Arm fat percentage (right)                 | 9.45E-10   | -0.0113377| 331249    | 4_89737558_C_G   | G             |
| rs7695177 | Trunk fat mass                             | 1.36E-09   | -0.0148679| 331093    | 4_89737558_C_G   | G             |
Table S3. The primers used for molecular cloning of reporter constructs. Related to Figure 1.
FWD: forward orientation; REV: reverse orientation

| Primers                | Sequence                                       | Product (bp) |
|------------------------|------------------------------------------------|--------------|
| FAM13A Promoter-FWD    | GAAGTGATGGTCTGGACTATGTT                        | 920          |
| FAM13A Promoter-REV    | CTACTCCTTCTGCCCTCAATG                         | 920          |
| rs2167750-WT-FWD-C     | TGAACACAATTTAGAATTCATCCGATTTCC                 | 538          |
| rs2167750-MUT-FWD-T    | TGTAGCTCTTTAGATTTAGACTATTATTTAGGTCTATA         | 538          |
| rs2167750-WT-REV-G     | TTCTTGACATATAAAACACTATGCCTTTCC                | 538          |
| rs2167750-MUT-REV-A    | GGAAGAACATTTATCATATAGACCTAAATAATATGTC         | 538          |
| rs2276936-WT-FWD-A     | CTCCAGCAAGTCTGTCGTC                           | 503          |
| rs2276936-MUT-FWD-C    | GGCTTTAATGTGCTAAATCAACATTTTGACAGCTAG          | 503          |
| rs2276936-WT-REV-T     | AGTATGTAACATTTAAAGGTTGTATATGT                | 503          |
| rs2276936-MUT-REV-G    | TCAATTTTACTAACATTTGCTACATTTCAAAAATGGT         | 503          |
| rs7695177-WT-FWD-C     | ATAGGAATTCATTTTCCTAAACTGC                    | 501          |
| rs7695177-MUT-FWD-G    | AAGGACTGAAACACACATTTGCTACATTTCTAA            | 501          |
| rs7695177-WT-REV-G     | AGGGAAGATCTATTGCTACATTTAAA                   | 501          |
| rs7695177-MUT-REV-C    | ATGGGAAAGTTTAGAATTTGTGGACTATAGTTGC           | 501          |

Table S4. Sequence of gRNAs used for deletion generation nearby the rs2276936. Related to Figure 1.

| Primers          | Sequence                                         | Deletion size (~bp) |
|------------------|--------------------------------------------------|---------------------|
| Rs227-1 upper    | 5’-CACCCTTATAATTTCCCTTTTAGCTC-3’                 | 148                 |
| Rs227-1 lower    | 5’-CACCCTTATAATTTCCCTTTTAGCTC-3’                 | 148                 |
| Rs227-2 upper    | 5’-CACCCTTATAATTTCCCTTTTAGCTC-3’                 | 117                 |
| Rs227-2 lower    | 5’-CACCCTTATAATTTCCCTTTTAGCTC-3’                 | 117                 |
TRANSPARENT METHODS

Open Chromatin Region Analysis

All liver-related and publicly available datasets of ATAC-Seq and DNase-Seq (bigwig files) were generated from Roadmap Epigenomics Project (Ernst and Kellis, 2015; Kundaje et al., 2015) and The Encyclopedia of DNA Elements (ENCODE) project (Inoue et al., 2017; Kazachenka et al., 2018). The genomic region of 89,706,500 - 89,752,000 on Chromatin 4 (GRCh37/hg19 as the reference genome) was shown with signal intensities across selected epigenomic datasets with IGV at version 2.5.3 (Broad Institute). Total open chromatin score was calculated as the mean value of all corresponding used datasets.

Animals

All animal studies were performed under the guidelines for the treatment of laboratory animals and approved by the Institutional Animal Care and Use Committee, Brigham and Women’s Hospital. Fam13a−/− mice in the C57BL/6 background were generated as previously described (Jiang et al., 2016). Briefly, Fam13a knockout embryonic stem cells in C57Bl/6 N background were injected to C57BL/6 J mice for germline transmission followed by ~3 generation of crossing into C57BL/6 J background. Background- and age-matched littermates were used as Fam13a+/+ controls. Normal chow- (containing 5.6% fat and 20% protein) fed Fam13a−/− and Fam13a+/+ mice were performed in 2 groups (n = 5-7 per genotype, 2-5 months old). Four-to five-months-old female mice were fed with HFD containing 36% fat, 35.7% carbohydrates, and 20.5% protein (F3282, Bio-Serv, Flemington, NJ) for 4 months. Two batches of experimental repeats were performed with 5-6 mice/group in each repeat. These mice were fed ad libitum and housed in a quiet room without disturbance of their sleep/wake behavior to reduce environmental stress in the animal facility of Brigham and Women’s Hospital.
Metabolic Studies

To determine roles of FAM13A in hepatic insulin signaling, insulin (5 U/kg, R-100, Eli Lilly and Company, Indianapolis, IN) was injected through the portal vein in mice after overnight fasting and tissue samples were collected before and 5 minutes after insulin injection as described previously (Jacobi et al., 2015). Briefly, a piece of liver was tied tightly by suture and then removed before insulin injection with no bleeding. Five minutes later after injection, another piece of liver sample was also collected in the same animal. Body compositions of mice including lean mass and fat mass were measured in mice using magnetic resonance imaging (MRI) by Brigham and Women’s Metabolic Core. Oxygen consumption (VO2), energy expenditure (EE), respiratory exchange rate and food intake were measured in mice fed with HFD for 7 weeks by Brigham and Women’s Metabolic Core. Lipolysis assay was performed as previously described (Rohm et al., 2013). Briefly, mice were fasted overnight with free access to water. Isoproterenol (I6504, Millipore Sigma, St. Louis, MO) dissolved freshly in PBS was injected by i.p. at 10 mg/kg body weight. Thirty minutes later, plasma samples were collected and free fatty acid was measured with free fatty acid quantification kit (MAK044, Millipore Sigma, St. Louis, MO). Fasting glucose was determined after overnight fasting. ITT (Insulin tolerance test) and GTT (Glucose tolerance test) were performed as described previously (Stanya et al., 2013) with human insulin (1 U/kg) (R-100, Eli Lilly and Company, Indianapolis, IN) after a 6-hour fasting or glucose (1.5 g/kg) after overnight fasting by i.p. injection, respectively. Blood glucose was measured before and after injection at the indicated time points using a glucometer (FreeStyle Precision Neo). Insulin concentrations in serum was measured using a commercial kit (EZRMI-13K, Millipore Sigma, St. Louis, MO). Blood and hepatic free fatty acid (MAK044, Millipore Sigma, St. Louis, MO), triglycerides (TR22421, Thermo Scientific, Waltham, MA) and cholesterol (ab65390, Abcam, Cambridge, MA) levels were measured using commercial kits based on manufacturer’s instruction. Hepatic lipids were extracted as described previously (Akiyama et al., 2004; Liu et al., 2011). Frozen liver samples (10-20 mg) were
homogenized in 500 µl lysis buffer (50 mM Tris (pH 8.0), 100 mM NaCl and 0.1% NP40) and then dried using Speed Vacuum. Lipids were thus extracted from dried tissues by chloroform: methanol (2:1 V/V) followed by measurements on free fatty acid, triglycerides and cholesterol assays using kits as described above.

**Primary hepatocytes isolation and glucose production assays**

Primary hepatocytes were isolated from anesthetized animals perfused with a collagenase solution (Liberase TM, Roche, Basel, Switzerland) in situ through the portal vein (Liu et al., 2013). Cells were liberated into DMEM after perfusion. A 45% Percoll (GE Lifescience, Marlborough, MA) gradient was used to separate live and dead hepatocytes. For glucose production measurements ex vivo, murine hepatocytes were cultured in DMEM with glucose (1.5 g/L) for 2 hours after serum withdrawal. Cells were then incubated in glucose production media (DMEM without glucose or phenol red, supplemented with 4 mM L-glutamine, 1 mM pyruvate and 10 mM sodium lactate) for 4 hours. Glucose concentrations in the media were measured by glucose assay kit (GAGO-20, Millipore Sigma, St. Louis, MO). Total protein amount of hepatocyte was measured by BCA protein assays (Thermo Scientific, Waltham, MA) for normalization.

**Measurements of Mitochondrial Respiration**

Extracellular Flux Analyzer (Seahorse Bioscience) was used to measure oxygen consumption rate (OCR), an indicator of mitochondrial respiration, in primary murine hepatocytes and HepG2 cells. Briefly, isolated hepatocytes or HepG2 cells were seeded directly into XF24 plates at a density of 2.5 x 10⁴ or 4 x 10⁴ cells/well, respectively. Mitochondrial respiration was measured on the next day in Agilent Seahorse XF Base Medium (Agilent Technologies) supplemented with pyruvate (10 mM) using the Seahorse XF Cell Mito Stress Test program. During the assay, oligomycin (2 mM), carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 1 mM) and actinomycin/rotenone (1 mM of
each) were sequentially added into each well for measurements on basal respiration, ATP production, maximum respiration, and proton leak (complex I driven), respectively.

**Histology**

Liver samples were fixed with 10% buffered formalin and embedded in paraffin. Hematoxylin and eosin staining was performed by InvivoEx LLC (InvivoEx LLC, Waltham, MA).

**Cell culture and transfection**

Embryonic kidney epithelial cells (HEK 293) and human hepatoma HepG2 cells were obtained from ATCC (American Type Culture Collection) and cultured in Dulbecco’s modified Eagle medium or Eagle's Minimal Essential Medium (EMEM), respectively, supplemented with 10% fetal bovine serum, penicillin (50 units/ml), and streptomycin (50 µg/ml). Expression constructs of Flag/Myc-tagged FAM13A (NP_001252507.1) (Jiang et al., 2016) and HA-tagged AMPKα1 or AMPKα2 (Wan et al., 2018) were transfected into cells using lipofectamine 3000 (Invitrogen, Carlsbad, CA) as the manufacturer recommended. Cells were used for various experiments 48 hours after transfection.

**RNA interference**

HepG2 cells were transfected with 50 nM FAM13A siRNA (L-020516-00-0020, Lafayette, CO) or non-target control siRNA (D-001810-10-20, Lafayette, CO) using Lipofectamine RNAiMAX transfection reagent (13778150, Thermo Scientific, Waltham, MA) according to the manufacturer’s instruction. Samples were harvested 48 hours after transfection. To produce FAM13A and AMPK shRNA containing lentivirus, HEK293T cells were co-transfected lentiFAM13A shRNA (1007266a, abmgood, Richmond, BC, Canada) and/or lentiAMPK shRNA (1000086a, abmgood, Richmond, BC, Canada) with psPAX2 and pMD2.G using lipofectamine 3000. Lentiviruses were collected after 48
h and then infected HepG2 cells for 24 h in the presence of 8 µg/ml polybrene (TR-1003-G, MilliporeSigma, Burlington, MA) and selected with 2 µg/ml of puromycin (P8833, Millipore Sigma, Burlington, MA).

RNA Extraction and Quantitative Real-time PCR
Total RNA was extracted from cells or frozen tissues using QIAzol lysis reagent (79306, Qiagen, Venlo, Netherlands) and the RNeasy mini kit (74106, Qiagen, Venlo, Netherlands). cDNA was obtained using high-capacity cDNA reverse transcription kit (4374966, Thermo Scientific, Waltham, MA). Relative gene expression was conducted by real-time PCR using TaqMan assays (4444964, Thermo Scientific, Waltham, MA) in a QuantStudio 12K machine (Life Technologies, Carlsbad, CA) and normalized to Rplp0 expression. TaqMan probes purchased from Integrated DNA Technologies (IDT, Skokie, IL) including human FAM13A (Hs.PT.58.1607079), human GAPDH (Hs.PT.39a.22214836), mouse FAM13A (Mm.PT.56a.42496772), mouse Fasn (Mm.PT.58.41299055), mouse Apoal (Mm.PT.58.11772461), mouse Srebfl (Mm.PT.58.8508227), mouse IL-6 (Mm.PT.58.10005566), mouse IFN-γ (Mm.PT.58.41769240), mouse MMP-9 (Mm.PT.58.10100097), mouse IL-10 (Mm.PT.58.13531087), mouse TNF (Mm.PT.58.12575861), mouse IL-1β (Mm.PT.58.41616450), mouse F4/80 (Mm.PT.58.11087779), mouse Acadm (Mm.PT.58.9316361), mouse Ppargc1α (Mm.PT.58.16192665), mouse Cpt1a (Mm.PT.58.10147164) and mouse Rplp0 (Mm.PT.58.43894205). All samples were assayed in duplicate in quantitative real-time PCR. Expression levels of target genes were calculated based on the $2^{-\Delta\Delta C_{t}}$ method.

Molecular Cloning and Reporter Assays
We engineered reporter constructs for each of the three SNPs (rs2167750, rs2276936, and rs7695177) into pGL4.32 luciferase construct. SNP-containing oligonucleotides were cloned into the pGL3-Basic
vector (Promega, Madison, WI) and the FAM13A promoter was inserted to the upstream of the luciferase gene. The primer sequences are shown in Supplementary Table 3. For each SNP, we tested both forward and reverse orientations, resulting in 4 unique oligonucleotide contexts. All plasmids used for reporter assays were confirmed by sequencing. We performed reporter assays in HepG2 cells as previously described (Castaldi et al., 2019). Briefly, 70% confluent HepG2 cells were plated into a 24-well plate. Eighteen hours later, cells were collected to measure enhancer activity using the Dual-Luciferase Reporter Assay System (E1960, Promega, Madison, WI) according to the manufacturer’s protocol. Luminescence signals were captured in GloMax GM2010 plate reader (Promega, Madison, WI). Independent transfection and reporter assays (triplicates) were performed four times.

CRISPR/CAS9 FAM13A Gene Knockout

To generate the DNA regional deletion spanning rs2276936, we designed 2 pairs of gRNA (rs227-1 and rs227-2) encompassing this SNP. The sequences of gRNAs are shown in Supplementary Table 4. gRNA pairs were cloned into pSpCas9 (BB)-2A-Puro (PX459) V2.0 vectors (Addgene #62988). To generate the small indel deletion nearby rs2276936, single guide RNA (5’-GCTAAATCAACATTTTTTAC-3’) spanning this SNP was cloned into PX459 and confirmed by sequencing. PX459 constructs with or without gRNA were transfected into HepG2 cells with Lipofectamine 3000 (L3000015, Fisher Scientific, Hampton, NH). After puromycin (ant-pr-1, InvivoGen, San Diego, CA) selection at 1.5 µg/mL, cells were recovered for 3-5 days and expanded for RNA extraction and quantitative real-time PCR.

Immunoblotting

Cells and tissues were lysed in lysis buffer with protease inhibitor cocktail (11697498001, Millipore Sigma, St. Louis, MO) and phosphatase inhibitor (NC0831193, Fisher Scientific, Hampton, NH). Lysates were cleared by centrifugation at 4°C at 14,000 rpm for 10 mins and protein concentrations
were determined by the Bradford method. Antibodies against the following proteins were used for western blotting: p-Akt (Thr308, #2965), Akt (#4691), p-AMPK (Thr172, #2535), AMPK (#2532), IRS-1 (#2382) from Cell Signaling (Danvers, MA). Anti-flag (#F1804) and anti-vinculin (#V-4505) antibodies were from Millipore Sigma (St. Louis, MO). Anti-FAM13A (#ab122440), anti-β-Actin (#ab20272) and anti-α-Tubulin (#ab185067) were obtained from Abcam (Cambridge, MA). Anti-Myc (#05-419) was purchased from Millipore (Burlington, MA). Densitometry of immunoblotting was analyzed using NIH Image J software.

Statistical Analyses

Statistics analyses were performed using unpaired Student’s t test. Data are presented as means ± SEM for in vivo studies. For in vitro assays, means ± SD were obtained from at least three biological replicates. Significance was claimed if established at p < 0.05.

Supplemental References

Akiyama, T.E., Lambert, G., Nicol, C.J., Matsusue, K., Peters, J.M., Brewer, H.B., Jr., and Gonzalez, F.J. (2004). Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. J Biol Chem 279, 20874-20881.

Castaldi, P.J., Guo, F., Qiao, D., Du, F., Naing, Z.Z.C., Li, Y., Pham, B., Mikkelsen, T.S., Cho, M.H., Silverman, E.K., et al. (2019). Identification of Functional Variants in the FAM13A Chronic Obstructive Pulmonary Disease Genome-Wide Association Study Locus by Massively Parallel Reporter Assays. Am J Respir Crit Care Med 199, 52-61.

Ernst, J., and Kellis, M. (2015). Large-scale imputation of epigenomic datasets for systematic annotation of diverse human tissues. Nat Biotechnol 33, 364-376.

Inoue, F., Kircher, M., Martin, B., Cooper, G.M., Witten, D.M., McManus, M.T., Ahituv, N., and Shendure, J. (2017). A systematic comparison reveals substantial differences in chromosomal versus episomal encoding of enhancer activity. Genome Res 27, 38-52.

Jacobi, D., Liu, S., Burkewitz, K., Kory, N., Knudsen, N.H., Alexander, R.K., Unluturk, U., Li, X., Kong, X., Hyde, A.L., et al. (2015). Hepatic Bmal1 Regulates Rhythmic Mitochondrial Dynamics and Promotes Metabolic Fitness. Cell Metab 22, 709-720.

Jiang, Z., Lao, T., Qiu, W., Polverino, F., Gupta, K., Guo, F., Mancini, J.D., Naing, Z.Z., Cho, M.H., Castaldi, P.J., et al. (2016). A Chronic Obstructive Pulmonary Disease Susceptibility Gene, FAM13A, Regulates Protein Stability of beta-Catenin. Am J Respir Crit Care Med 194, 185-197.
Kazachenka, A., Bertozzi, T.M., Sjoberg-Herrera, M.K., Walker, N., Gardner, J., Gunning, R., Pahita, E., Adams, S., Adams, D., and Ferguson-Smith, A.C. (2018). Identification, Characterization, and Heritability of Murine Metastable Epialleles: Implications for Non-genetic Inheritance. Cell 175, 1259-1271 e1213.

Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., Ziller, M.J., et al. (2015). Integrative analysis of 111 reference human epigenomes. Nature 518, 317-330.

Liu, S., Brown, J.D., Stanya, K.J., Homan, E., Leidl, M., Inouye, K., Bhargava, P., Gangl, M.R., Dai, L., Hatano, B., et al. (2013). A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature 502, 550-554.

Liu, S., Hatano, B., Zhao, M., Yen, C.C., Kang, K., Reilly, S.M., Gangl, M.R., Gorgun, C., Balschi, J.A., Ntambi, J.M., et al. (2011). Role of peroxisome proliferator-activated receptor \( \delta/\beta \) in hepatic metabolic regulation. J Biol Chem 286, 1237-1247.

Rohm, M., Sommerfeld, A., Strzoda, D., Jones, A., Sijmonsma, T.P., Rudofsky, G., Wolfrum, C., Sticht, C., Gretz, N., Zeyda, M., et al. (2013). Transcriptional cofactor TBLR1 controls lipid mobilization in white adipose tissue. Cell Metab 17, 575-585.

Stanya, K.J., Jacobi, D., Liu, S., Bhargava, P., Dai, L., Gangl, M.R., Inouye, K., Barlow, J.L., Ji, Y., Mizgerd, J.P., et al. (2013). Direct control of hepatic glucose production by interleukin-13 in mice. J Clin Invest 123, 261-271.

Wan, L., Xu, K., Wei, Y., Zhang, J., Han, T., Fry, C., Zhang, Z., Wang, Y.V., Huang, L., Yuan, M., et al. (2018). Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Mol Cell 69, 279-291 e275.